Article and Video CATEGORIES
Here is the next portion of our special webinar on molecular markers in advanced NSCLC, featuring Drs. Charlie Rudin from Johns Hopkins, Dr. Alice Shaw from Massachusetts General Hospital, Dr. David Spigel from Sarah Cannon Cancer Center, and Dr. Glen Goss from the University of Ottawa and NCI-Canada's Lung Cancer Committee.
In this continuing portion of the program, we have a debate on the merits of uniform vs. more selective testing of "druggable" mutations and consider whether it is more attractive to test for multiple markers simultaneous or perhaps sequentially, since they are typically mutually exclusive. We also discuss the challenge of the delays in treatment that may become a real clinical problem for some patients if testing may require a few weeks of downtime.
Below you'll find the audio and video versions of the podcast, along with the transcript and figures for this activity.
[powerpress]
Molecular Markers SM Pt 3 Panel Discussion Audio Podcast
Molecular Markers SM Pt 3 Panel Discussion Transcript
Molecular Markers SM Pt 3 Panel Discussion Figs
We'll continue this rather intense discussion in the next podcast, coming soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3
It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...
Thank you Dr. West. So glad you asked Blaze and glad I reached out to you Dr. West.
Blaze, Dr. West wrote, "Because I’m now working for a biopharma company...
Hi and welcome to GRACE. I'm sorry your mom is having this difficulty. An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...
Hi Blaze,
As much as I hate to say it, Welcome back Blaze. It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...